Stevioside Attenuates Insulin Resistance in Skeletal Muscle by Facilitating IR/IRS-1/Akt/GLUT 4 Signaling Pathways:

Abilasha Deenadayalan1,2, Vijayalakshmi Subramanian1, Vijayalakshmi Paramasivan3

  • 1Department of Anatomy, Saveetha Institute of Medical & Technical Sciences, Chennai 602 105, India.

Insights

Stevioside, a natural compound, effectively combats oxidative stress and enhances glucose uptake in type-2 diabetes by activating key insulin signaling pathways in muscles, similar to metformin.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Metabolic Disorders

Background:

  • Type-2 diabetes mellitus (T2DM) is a significant global health issue, often linked to obesity and oxidative stress in skeletal muscles.
  • Developing novel therapeutic agents to mitigate these pathological processes is a critical medical priority.

Purpose of the Study:

  • To investigate the potential of Stevioside, a compound from *Stevia rebaudiana*, in managing T2DM.
  • To analyze its effects on insulin signaling molecules within the gastrocnemius muscle of rats with diet-induced obesity and hyperglycemia.

Main Methods:

  • Rats were induced with T2DM using a high-fat diet and sucrose, then treated with Stevioside (20 mg/kg/day) for 45 days.
  • Evaluated parameters included blood glucose, lipid profile, oxidative stress markers, antioxidant enzymes, and insulin signaling proteins (IR, IRS-1, Akt, GLUT 4).
  • In silico molecular docking was performed to assess binding affinities with IRS-1 and GLUT 4.

Main Results:

  • Stevioside treatment improved glucose and insulin tolerance, normalizing fasting blood glucose and serum lipid profiles.
  • It reduced oxidative stress markers (LPO, H2O2, OH*) and enhanced antioxidant enzyme activity (CAT, SOD, GPx, GSH) in diabetic muscles.
  • Stevioside upregulated insulin signaling molecules (IR, IRS-1, Akt mRNA) and augmented glucose transporter 4 (GLUT 4) synthesis, promoting glucose uptake and oxidation.

Conclusions:

  • Stevioside effectively inhibits oxidative stress and promotes glucose uptake in T2DM skeletal muscles via the IR/IRS-1/Akt/GLUT 4 pathway.
  • Its efficacy in vivo and in silico suggests Stevioside is a promising phytomedicine for T2DM treatment.

Related Concept Videos

Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
465
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
280
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
334
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
1.5K